-
ArticlePublication 2007Measuring Health Preferences for Use in Analyses of Interventions in Children
Valuing the health of children for cost-utility or cost-benefit analysis is more challenging than valuing …
Valuing the health of children for cost-utility or cost-benefit analysis is more challenging than valuing adult health. Young children cannot conceptualize value, they are not responsible for their own decision making, and proxies may not fully understand the child perspective. Moreover illness in children may affect parent/caregiver health and quality of life, further complicating the measurement of value associated with a change in a child’s health status.This paper reviews the most common approaches (QALYs and willingness-to-pay)…
Europe | Preferences/Values | Health Outcomes | Infectious Diseases | Child/Nutrition | North America -
ArticlePublication 2016Cost-Effectiveness of a Herpes Zoster Vaccination Program among the French Elderly People
This study reports on a cost-effectiveness analysis of herpes zoster (HZ) vaccines among the elderly …
This study reports on a cost-effectiveness analysis of herpes zoster (HZ) vaccines among the elderly in France. Starting vaccination in individuals aged 65, 70 and 75 years old appears more cost-effective than vaccination for beginning vaccination at age 60, with a cost-effectiveness ratio between 30,000 and 35,000 euros per quality-adjusted-life year (QALY) gained for the 65 and 70-year age groups versus 54,500 euros for the age 75 group. These results largely contributed to the recommendation…
Europe | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine -
ArticlePublication 2013Vaccination against Herpes Zoster and Postherpetic Neuralgia in France: A Cost-Effectiveness Analysis
This article reports on a cost-effectiveness analysis of the original herpes zoster vaccine (ZVL) for …
This article reports on a cost-effectiveness analysis of the original herpes zoster vaccine (ZVL) for the 65 year + population in France. The authors compared vaccinating all adults over 65 years versus adults from 70-79 years, over their lifetimes, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol 5D) utilities from the literature. Results showed incremental cost-effective ratios d between €9513 and €12,304 per quality-adjusted life…
Europe | Preferences/Values | State-Transition | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine -
ArticlePublication 2015Distribution of Health Effects and Cost-Effectiveness of Varicella Vaccination
This article reports on an analysis of the impact of universal childhood varicella vaccination on the …
This article reports on an analysis of the impact of universal childhood varicella vaccination on the incidence of herpes zoster (HZ) using dynamic transmission modelling and cost-effectiveness analyses. Scenarios that are considered differ by whether or not immune boosting is included, and whether or not reactivation of vaccine virus is possible. The authors report that health effects of varicella vaccination in scenarios with immune boosting are unevenly distributed: cohorts born just before introduction of vaccination and…
Europe | Preferences/Values | Dynamic Transmission | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine -
ReviewPublication 2015Humanistic, Economic and Societal Burden of Herpes Zoster in Europe
This review provides documentation and critical appraisal of published data concerning the humanistic, economic and …
This review provides documentation and critical appraisal of published data concerning the humanistic, economic and societal burden of herpes zoster (HZ) in Europe. From a review of 1619 abstracts, 53 eligible articles, were identified which reported data concerning healthcare resource use (n = 38), direct costs (n = 20), indirect costs (n = 16), total costs (n = 10) and impact on health-related quality of life (HRQoL) (n = 21).The findings indicate that postherpetic neuralgia…
Europe | Preferences/Values | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases
5 Shown
General Resources
Teaching Resources
Collections
Format
Learner Level
Teaching Topic